Zimmer Biomet Holdings (XSWX:ZBH) Moat Score: 7/10 (As of Jun. 30, 2026)


XSWX:ZBH Zimmer Biomet Holdings Inc XSWX:ZBH
65 GF Score
Price CHF74.50
GF Value CHF102.97
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Moat Score?

Zimmer Biomet Holdings XSWX:ZBH 65 Moat Score is 7 as of Jun. 30, 2026. GuruFocus rates XSWX:ZBH with a GF Score™ of 65/100 and a GF Value™ of CHF102.97 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 98.94% on this metric.

Zimmer Biomet Holdings has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Zimmer Biomet Holdings has Wide Moat: Zimmer Biomet Holdings Inc has a strong market leadership in the medical devices sector, with significant customer switching costs and valuable patents. The company benefits from economies of scale, strong brand strength, and regulatory barriers. Its innovation and R&D capabilities support its durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zimmer Biomet Holdings might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Zimmer Biomet Holdings  (XSWX:ZBH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zimmer Biomet Holdings Moat Score Related Terms

XSWX:ZBH vs STE, PEN, GMED: Moat Score Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zimmer Biomet Holdings Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Moat Score falls into.


XSWX:ZBH
65GF Score
Zimmer Biomet Holdings Inc XSWX:ZBH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a Moat Score of 7 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Zimmer Biomet Holdings ranks #9 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is Zimmer Biomet Holdings' Moat Score too high?
Zimmer Biomet Holdings' current Moat Score is 7. Based on the distribution chart, Zimmer Biomet Holdings ranks #9 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zimmer Biomet Holdings has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Moat Score compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #9 out of 846 companies for Moat Score. This places Zimmer Biomet Holdings in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Zimmer Biomet Holdings's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF102.97, compared to a current price of CHF74.50 — trading 27.6% below its estimated fair value. The current Moat Score is 7. Zimmer Biomet Holdings' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Moat Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of CHF74.50 is trading 27.6% below its estimated GF Value™ of CHF102.97. GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.

Key valuation signals for XSWX:ZBH:

  • Moat Score: 7
  • GF Value™: CHF102.97 vs. price of CHF74.50 (27.6% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
65GF Score

Get the complete analysis for XSWX:ZBH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF74.50
Price
CHF102.97
GF Value